Therefore, high cyclin D expression, low CDKN2A expression, and CDK4 overexpression suggest CDK4 is a potential target for NSCLC, lung, esophageal, colorectal, kidney, pancreatic, liver, breast, prostate, and cervical carcinomas, melanoma, liposarcoma, myeloma, medulloblastoma, mantle cell, and acute lymphoblastic lymphoma treatments [61]. This evidence concerns the gene CDK4 and melanoma.